Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

31.10
-0.0200-0.06%
Post-market: 31.510.4100+1.32%16:27 EDT
Volume:754.99K
Turnover:23.73M
Market Cap:2.17B
PE:-10.39
High:31.96
Open:31.14
Low:31.09
Close:31.12
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:44.23M
Volume Ratio:1.20
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:6.45
PE(LYR):-8.92

Loading ...

Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR

TIPRANKS
·
Sep 08

Pharvaris announces positive topline data from deucrictibant in HAE attacks

TIPRANKS
·
Sep 08

Pharvaris Says Phase 3 Chapter-3 Trial Shows 83% Cut in HAE Attack Rate for Deucrictibant XR vs Placebo

Reuters
·
Sep 08

Pharvaris N.v. - Plans to Submit Nda to FDA for Deucrictibant Xr in First Half 2027

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - All Secondary Efficacy Endpoints Met with Statistical Significance in Chapter-3 Study

THOMSON REUTERS
·
Sep 08

Pharvaris Announces Positive Topline Data from Chapter-3 Pivotal Study of Deucrictibant Xr for Prophylaxis of Hae Attacks

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Topline Data from Creaate Phase 3 Study Expected First Quarter 2027

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Chapter-3 Study Met Primary Endpoint with 83% Attack Rate Reduction Versus Placebo

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - 87% Attack Rate Reduction Versus Placebo in Hae Type 1 or Type 2 Patients

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Deucrictibant Xr Demonstrated Well-Tolerated Safety Profile in Chapter-3 Study

THOMSON REUTERS
·
Sep 08

Pharvaris Reports Phase 2 Chapter-1 Extension Data Showing Long-Term Safety, Attack-Rate Drop for Deucrictibant in HAE

Reuters
·
Sep 03

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

TIPRANKS
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Aug 14

Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says

MT Newswires Live
·
Aug 14

Pharvaris N.v. : Bofa Global Research Raises Price Objective to $38 from $35

THOMSON REUTERS
·
Aug 13

ProQR Q2 Revenue More than Doubles

Reuters
·
Aug 13

RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 13

Pharvaris N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Pharvaris' Q2 Loss Per Share Narrows

MT Newswires Live
·
Aug 12

Switzerland's Pharvaris Q2 Loss Narrows, Cash Rises to €318 Mln

Reuters
·
Aug 12